TR107 exhibits nanomolar antitumor activity against triple-negative breast cancer SUM159 and MDA-MB231 cells and degrades the essential proteins of oxidative phosphorylation and tricarboxylic acid cycle pathways via ClpP by generating a ClpP-KO cell line (47). The gene discussed is CLPP; the disease is triple-negative breast carcinoma.